Evotec and Janssen team up in immunooncology
Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Evidence of deliberate climate damage
/in News/by Thomas GabrielczykA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
New polymer can stop biofilm formation
/in News/by Thomas GabrielczykBritish researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Rewind Therapeutics extends Series A financing
/in News/by Thomas GabrielczykWith Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
Henkel buys FDCA from Avantium NV
/in News/by Thomas GabrielczykBioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.
Vésale Bioscience wins R&D grant
/in News/by Thomas GabrielczykPhage therapy specialist Vésale Bioscience gas bageds 1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
Abionyx Pharma announces success in fighting sepsis-triggered AKI
/in News/by Thomas GabrielczykAbionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury […]
BioNTech bags Instadeep for £562m
/in News/by Thomas GabrielczykBioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Roche withdraws checkpoint blocker from the market
/in News/by Thomas GabrielczykRoche AGs US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
/in News/by Thomas GabrielczykWith the help of a 25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.